Vandria Reports Positive Phase 1 Target Engagement Data for VNA-318, Supporting Further Development in Alzheimer’s Disease
VNA-318, an oral brain-penetrant small molecule therapeutic modulates a novel target to reduce inflammation and improve mitochondrial function First-in-human trial showed a highly favourable safety profile, with VNA-318 well tolerated across all dose levels without any safety concerns Single doses of VNA-318 resulted in a statistically significant (p<0.001) and dose-dependent change in a key plasma […]